ARCHIVES

Phase III Study: Rituxan Improved PFS By 79% In Advanced Follicular Lymphoma

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

January 21, 2005

Nancy Davidson Named Director Of UPCI, Succeeding Herberman.

November 21, 2008

Rauscher Tells Flood Subcommittee How He Would Spend An Extra $50 Million-On Centers, Grants

April 12, 1974

Clinical Trials Approved By NCI Last Month

March 29, 2002

ODAC Calls For Tougher Standards For Accelerated Approval In Oncology

February 11, 2011

Radiation To Stem Cell Niche Improved PFS In Glioblastoma

August 27, 2010